Abstract:Point mutations within the DNA-binding domain of the TP53 gene occur in a significant percentage of human cancer, leading to cellular accumulation of highly stabilized mutant p53 proteins (mutp53) with tumor-promoting properties. Depletion of mutp53, through inducing either autophagic or proteasomal degradation, is an attractive strategy for the therapy of p53-mutated cancer, but the currently-known degradation inducers, almost exclusively small molecules, are inadequate. Here we show that pH-responsive zeolitic imidazolate framework-8 (ZIF-8) offers a novel solution to mutp53 degradation. ZIF-8 facilitated ubiquitination-mediated and glutathionylation-dependent proteasomal degradation of all of the nine mutp53 we tested, including six hot-spot mutp53, but not the wild-type p53 protein. Sustained elevation of intracellular Zn++ level, resulted from decomposition of the internalized ZIF-8 in the acidic endosomes, decreased the intracellular reduced glutathione (GSH): oxidized glutathione (GSSG) ratio and was essential for mutp53 glutathionylation and degradation. ZIF-8 modified with an Z1-RGD peptide, exhibiting enhanced cellular internalization and improved decomposition behavior, preferentially killed mutp53-expressing cancer cells and demonstrated remarkable therapeutic efficacy in a p53 S241F ES-2 ovarian cancer model as well as in a p53 Y220C patient-derived xenograft (PDX) breast cancer model. The ability to induce wide-spectrum mutp53 degradation gives ZIF-8 a clear advantage over other degradation-inducers, and engineered nanomaterials may be promising alternatives to small molecules for the development of mutp53-targeting drugs.

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer

Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

Targeting mutant p53 stabilization for cancer therapy

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Design, Synthesis, and Evaluation of p53Y220C Acetylation Targeting Chimeras (AceTACs)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8

Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy

Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation

Targeting P53 for Novel Anticancer Therapy.

The Janus Face of P53-Targeting Ubiquitin Ligases

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Activating p53 with a Mutant-Specific Small Molecule

PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: an Updated Perspective.